Nausea
Conditions
Brief summary
In this pilot study, the Baxter Retching Faces (BARF) Scale will be used to assess chemotherapy induced nausea and vomiting (CINV) in the pediatric cancer population during chemotherapy admissions, and the corresponding administration of anti-emetic medications will be reviewed.
Interventions
BEHAVIORALBaxter Retching Faces (BARF) scale
* Pictorial scale that was developed for use by pediatric patients in self-reported assessments of nausea severity * A patient will respond by choosing a picture or a number on the scale that best represents how they feel. The patient may speak or simply point to their response. While the numbers 0-2-4-6-8-10 are listed alongside the pictures, patients are also allowed to choose in between or odd numbers. If a patient is unwilling to participate, the patient's parent or guardian may serve as their proxy and choose a number for them, based off of their symptoms. * The BARF scale has 6 faces with assigned scores ranging from 0 to 10 with a score difference of 2 between each face (a higher score indicates more nausea).
Sponsors
Washington University School of Medicine
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
HEALTH_SERVICES_RESEARCH
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
4 Years to 12 Years
Healthy volunteers
No
Inclusion criteria
* Patients diagnosed with cancer of any kind. * Patients receiving inpatient chemotherapy at SLCH on the general pediatric oncology service * Patients admitted for a course of inpatient chemotherapy scheduled to last at least 24 hours and but no more than 7 days. * Patients who have received any prior cancer treatment, including radiation therapy, and/or surgery. * Patients ages 4 to 12 years of age. * Patient with a guardian who has the ability to understand English and the willingness to sign an IRB approved written informed consent document.
Exclusion criteria
* Any patient who is not undergoing inpatient chemotherapy on the general pediatric oncology service, including patients undergoing chemotherapy as conditioning for hematopoietic stem cell transplantation or other cellular therapy. * Any patient who is receiving their first cycle of inpatient chemotherapy (however, they can be included during a future cycle). * Any patient who is blind or unable to communicate by speaking or pointing.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Doses of anti-emetic medication administered during inpatient chemotherapy admissions | 24 hours - 7 days (estimated) |
Countries
United States
Outcome results
None listed